The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 3
Abstract
Objectives: Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir (PrOD) seems to be highly effective and safe in chronic haemodialysis (CHD) patients. We presented our experiences of treatment with PrOD in CHD patients. Materials and Methods: Between July 2016 and September 2018, a total of 25 CHD patients treated with PrOD were enrolled. The patients with hepatitis C virus (HCV) genotype 1a were treated with PrOD plus ribavirin (RBV) (12 or 24 weeks according to whether or not they had compensated cirrhosis), while the patients with genotype 1b were treated with PrOD alone. Liver functions, renal functions, and HCV-RNA levels were measured at baseline, 4, 12, and if applicable, 24 weeks after the initiation of treatment as well as 4 and 12 weeks after therapy. Results: Nineteen patients received PrOD, while 6 received PrOD plus RBV treatment. Two patients failed to complete the treatment. Two patients with compensated cirrhosis were treated over 24 weeks, while others received 12 weeks. In 23 patients completed 12 weeks, all were HCV-RNA negative at the end of the treatment, and had sustained virologic response (SVR) after the 12 weeks of treatment. The most common side effects were pruritus and anaemia. Conclusion: The PrOD treatment resulted in a high rate of SVR in HCV-infected CHD.
Authors and Affiliations
Nilay Danış, Hüsnü Pullukçu, Tansu Yamazhan, Galip Ersöz, Nalan Ünal, Fulya Günşar, İlker Turan, Zeki Karasu, Ulus Salih Akarca
Prevalence of Hepatitis B and C Infection in Patients with Rheumatoid Arthritis in Marrakesh
Objectives: Although there is no difference in frequency of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with rheumatoid arthritis (RA) in general population, multicenter studies are needed a...
Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report
Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been repor...
An Evaluation of the Efficacy of High-dose Hepatitis B Vaccine in Patients Using Biological Agents
Objectives: Hepatitis B virus (HBV) vaccination is efficient in the normal population, whereas lower humoral response rates in immunosuppressed patients. Biological agents used in the treatment of several diseases in rec...
Is There an Association Between Hepatitis B and Atherosclerosis?
Objectives: Although hepatitis B infection can cause chronic disease, its association with atherosclerosis is a matter of debate. Retinopathy is an early marker for microvascular abnormalities of retinal circulation and...
Genotype Distribution of Hepatitis C Virus and Demographic Features of The Patients in The Province of Karabük
Objectives: It was aimed to determine the distribution of hepatitis C virus (HCV) genotypes among patients who had HCV infection, and to identify the demographic characteristics of these patients. Materials and Methods:...